Pfizer Q4 FY26 Results: PAT Rs 199.82 Crore Revenue Rs 629.23 Crore

Pfizer Q4 FY26 results were announced on 12 May 2026, with the company reporting a consolidated net profit of Rs 199.82 crore for the quarter ended March 31, 2026. Revenue from operations stood at Rs 629.23 crore in Q4 FY26. The Pfizer Q4 FY26 performance will be assessed by investors against the broader macro backdrop of India’s economic recovery, sectoral dynamics in Pharmaceuticals, and management commentary on the FY27 outlook.

Click Here – Get Free Investment Predictions

Pfizer India FY26 revenue from operations rose 10.4 percent to Rs 2,519.65 crore. Q4 FY26 EPS was Rs 43.68. Total equity stood at Rs 4,202.90 crore. Exceptional items of Rs 49.16 crore for FY26 include Rs 41.73 crore for personnel separation costs related to an exclusive supply and marketing agreement with Cipla for four brands. The record date for the Rs 75 dividend is July 17, 2026.

Pfizer Q4 FY26 Key Financial Highlights

The following table summarises key Pfizer Q4 FY26 financial highlights as reported on 12 May 2026.

Parameter	Q4 FY26	Reference
Net Profit (PAT)	Rs 199.82 crore	Prior year period
Revenue from Operations	Rs 629.23 crore	Prior year period
FY26 Full Year PAT	Rs 722.43 crore	FY25 reference
Dividend	Rs 75 per share	Subject to AGM approval
NSE Ticker	PFIZER	Sector: Pharmaceuticals

Screen the best stocks on the Univest Screener.

Pfizer Q4 FY26 Profit Analysis

Pfizer Q4 FY26 net profit of Rs 199.82 crore represents the company’s quarterly performance in Pharmaceuticals. The growth was supported by strong operational execution, volume expansion and favourable cost dynamics. Investors will closely monitor management commentary on margin trajectory and FY27 guidance from these Pfizer Q4 FY26 results.

The Q4 FY26 performance places Pfizer among the outperformers in the Pharmaceuticals sector for the March 2026 quarter. The company operates in Pharmaceuticals, a sector that is closely watched for demand trends, margin recovery, and volume growth in the context of India’s overall economic momentum in FY27.

Revenue and Operating Performance in Pfizer Q4 FY26

The revenue performance in Pfizer Q4 FY26 reflects the operating dynamics of the Pharmaceuticals sector during the January to March 2026 quarter. The Pfizer Q4 FY26 operating performance will be evaluated against the context of broader industry trends, raw material costs, and demand conditions in the company’s key markets.

Management commentary on volume growth, pricing power, margin trajectory, and order book position will be key inputs for analysts revising their FY27 estimates following these Pfizer Q4 FY26 results.

Pfizer FY26 Full Year Performance

On a full-year basis, Pfizer reported consolidated net profit of Rs 722.43 crore for FY26. Revenue from operations for the full year stood at Rs 2519.65 crore. The quarterly performance in Q4 FY26 provides the base from which investors will assess FY27 guidance and earnings delivery. The Pfizer Q4 FY26 results thus cap a financial year marked by strong operational execution and margin improvement.

The board of Pfizer recommended a final dividend of Rs 75 per share for FY26, subject to shareholder approval at the ensuing Annual General Meeting.

Pfizer Q4 FY26 Stock Price and Market Position

Pfizer is listed on the NSE under the ticker PFIZER and operates in the Pharmaceuticals sector. Following the Pfizer Q4 FY26 results announcement on 12 May 2026, the stock will be assessed by the market based on the quarterly profitability trajectory, management commentary on FY27 outlook, and dividend decisionof Rs 75 per share. Investors should track live price movements and analyst rating changes on the Univest Screener.

Pfizer FY27 Outlook

Post Pfizer Q4 FY26 results, the key areas of investor focus for FY27 include management’s guidance on revenue growth, operating margin trajectory, capital expenditure plans, and demand visibility in the Pharmaceuticals sector. The strong Q4 FY26 performance sets a positive base for FY27 earnings delivery and potential re-rating of the stock. The broader macroeconomic backdrop of India’s continued growth momentum, RBI rate cuts, and sectoral policy tailwinds will also shape the FY27 earnings outlook for Pfizer.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Frequently Asked Questions on Pfizer Q4 FY26 Results

What is Pfizer Q4 FY26 net profit?

Ans. Pfizer Q4 FY26 consolidated net profit is Rs 199.82 crore.

When did Pfizer announce Q4 FY26 results?

Ans. Pfizer announced Q4 FY26 results on 12 May 2026, through a board meeting held on the same date, with filings submitted to BSE and NSE thereafter.

What was Pfizer revenue in Q4 FY26?

Ans.

Ans. Pfizer Q4 FY26 revenue from operations was Rs 629.23 crore.

What is Pfizer Q4 FY26 dividend?

Ans. The board of Pfizer recommended a final dividend of Rs 75 per share for FY26, subject to approval at the Annual General Meeting.

Where can I track Pfizer Q4 FY26 live price?

Ans. Track Pfizer live price, analyst ratings, and Q4 FY26 earnings updates on the Univest Screener for real-time data and research.

Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice. All financial data cited is sourced from BSE/NSE exchange filings and verified news sources. Investments in securities are subject to market risk. Consult a SEBI-registered investment advisor before making any investment decision.